Abstract 2031: Antitumoral synergy of iron chelators and chemotherapies in triple-negative breast cancer cell lines and patient-derived xenograft

MLA

Ivan Bièche, et al. “Abstract 2031: Antitumoral Synergy of Iron Chelators and Chemotherapies in Triple-Negative Breast Cancer Cell Lines and Patient-Derived Xenograft.” Cancer Research, vol. 77, July 2017, p. 2031. EBSCOhost, https://doi.org/10.1158/1538-7445.am2017-2031.

APA

Ivan Bièche, Sandrine Tury, Elisabetta Marangoni, Céline Callens, Véronique Becette, Sophie Vacher, Jean-Luc Servely, Franck Assayag, & Sophie Chateau-Joubert. (2017). Abstract 2031: Antitumoral synergy of iron chelators and chemotherapies in triple-negative breast cancer cell lines and patient-derived xenograft. Cancer Research, 77, 2031. https://doi.org/10.1158/1538-7445.am2017-2031

Chicago

Ivan Bièche, Sandrine Tury, Elisabetta Marangoni, Céline Callens, Véronique Becette, Sophie Vacher, Jean-Luc Servely, Franck Assayag, and Sophie Chateau-Joubert. 2017. “Abstract 2031: Antitumoral Synergy of Iron Chelators and Chemotherapies in Triple-Negative Breast Cancer Cell Lines and Patient-Derived Xenograft.” Cancer Research 77 (July): 2031. doi:10.1158/1538-7445.am2017-2031.